Xeinadin Mid Market Accountancy Firm Prepares For Sale Amid £800 Million Valuation Hopes

The mid-market accountancy firm Xeinadin is preparing for a potential sale that could fetch over £800 million. This move comes as private equity-backed deals continue to rise in the professional services sector, driven by significant investor interest. The sale is being spearheaded by the private equity firm Exponent, which acquired a stake in Xeinadin in 2021.

Advisers from Evercore, an investment bank, have been brought in to manage the auction, which is expected to begin in the coming weeks. Industry insiders have reported that Xeinadin’s projected earnings before interest, taxes, depreciation, and amortisation (EBITDA) stand at approximately £60 million. With accounting firms often being valued at around 14 times their EBITDA, this places Xeinadin’s potential value at just over £840 million. Still, some suggest the final sale price may fall short of this expectation.

Founded in 2019, Xeinadin operates an extensive network of more than 130 offices across the UK and Ireland. The firm emerged from the merger of over 100 accountancy companies and has since expanded through additional acquisitions. By consolidating firms, Xeinadin has followed a “roll-up” strategy, often used by private equity groups to drive scale and efficiency. Comparable models are employed by competitors such as Azets, another mid-market player.

The accounting sector has recently seen a surge in deals, with private equity firms heavily investing in mid-sized and smaller accountancy businesses. Grant Thornton, one of the UK’s largest auditors, recently sold a stake to Cinven, while Evelyn Partners secured backing from Apax. At the smaller end of the spectrum, firms like Smith & Williamson and Cooper Parry have rivalled to acquire other accountancies, underlining the strong demand for consolidation in the industry.

Despite the excitement, some investors have expressed concerns that optimistic valuations might be inflating a bubble within the accountancy sector. With competition among private equity-backed firms intensifying, there is cautious speculation about the long-term sustainability of these valuations.

For now, Xeinadin’s position as a leading consolidator within the market puts it in sharp focus for potential investors. The upcoming auction will reveal whether the firm can achieve the sought-after price point, or if market pressures will dictate a more modest result.